EMA’s CHMP (Committee for Medicinal Products for Human Use) offered a positive opinion for GW Pharmaceuticals Plc (NASDAQ:GWPH)’s Type II variant of Epidyolex to treat seizures...
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) agreed to pay $7.2 billion in stock and cash for Marijuana Derived Epilepsy Drug – Epidiolex developed by GW Pharmaceuticals Plc (NASDAQ:...
GW Pharmaceuticals Plc (NASDAQ:GWPH) reported $148.2 million (up 35.83% YoY) in total revenues in Q4 2020. Its full-year revenues are $572.2 million. CEO of GW Pharmaceuticals,...
GW Pharmaceuticals PLC (NASDAQ:GWPH) posted a growth of 68.4% YoY to $121.3 million in revenues in Q2 2020. CEO of GW Pharmaceuticals, Justin Gover, said the...
The Home Office in the UK changed GW Pharmaceuticals PLC (NASDAQ:GWPH)’s Epidyolex to schedule 5 from schedule 2. However, different legislation will be enacted in the...
